Given the important roles of class II HDACs in the pathogenesis of cardiac hypertrophy and for the maintenance of insulin sensitivity and energy balance (Zhang et al., 2002; Luan et al., 2014), these enzymes will be a potential target for drug development or disease control in the future. The gene discussed is INS; the disease is cardiac hypertrophy.